Elhan Webb
Investor Relations Contact bei KARYOPHARM THERAPEUTICS INC.
Profil
Elhan Webb is a professional who currently holds the position of Senior Vice President-Investor Relations at Karyopharm Therapeutics, Inc. She has previously worked as an Investor Relations Officer at Roche Holding AG, Head-Investor Relations & External Communications at Radius Health, Inc., and Vice President-Investor Relations at Rubius Therapeutics, Inc. Ms. Webb holds an MBA degree from the University of Southern California and an undergraduate degree from Bogazici University.
Aktive Positionen von Elhan Webb
| Unternehmen | Position | Beginn |
|---|---|---|
| KARYOPHARM THERAPEUTICS INC. | Investor Relations Contact | 14.03.2022 |
Ehemalige bekannte Positionen von Elhan Webb
| Unternehmen | Position | Ende |
|---|---|---|
| ROCHE HOLDING AG | Public Communications Contact | - |
| RUBIUS THERAPEUTICS | Investor Relations Contact | - |
| RADIUS HEALTH, INC. | Investor Relations Contact | - |
Ausbildung von Elhan Webb
| University of Southern California | Masters Business Admin |
| Bogazici University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ROCHE HOLDING AG | Health Technology |
| KARYOPHARM THERAPEUTICS INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
Rubius Therapeutics, Inc.
 Rubius Therapeutics, Inc. BiotechnologyHealth Technology Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA. | Health Technology |
